Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.

Endocrinol Diabetes Metab · 2026 · PMC13392217 · PMID 42487237

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a nonsignificant trendp = 0.05actually significant

The 24 mg dose and 3 mg dose demonstrated a nonsignificant trend toward BMI reduction ( p = 0.05).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.